Sirtsei Pharmaceuticals, Inc.
Clinical trials sponsored by Sirtsei Pharmaceuticals, Inc., explained in plain language.
-
New depression pill SP-624 enters Mid-Stage trial
Symptom relief CompletedThis study tests whether a daily oral drug called SP-624 can safely reduce depression symptoms in adults with major depressive disorder. About 456 participants will receive either SP-624 or a placebo for several weeks. The main goal is to see if SP-624 leads to a greater improvem…
Phase 2 • Sponsor: Sirtsei Pharmaceuticals, Inc. • Aim: Symptom relief
Last updated Aug 20, 2026 00:00 UTC
-
New drug SP-624 targets brain waves in depression study
Knowledge-focused CompletedThis completed Phase 1 trial tested whether the experimental drug SP-624 affects brain electrical activity in 26 people — some healthy, some with major depression. Participants took SP-624 or a placebo daily for two weeks. Researchers used EEG and AI to look for changes in brain …
Phase 1 • Sponsor: Sirtsei Pharmaceuticals, Inc. • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:38 UTC